IOVA News and Press, Iovance Biotherapeutics Inc. From 07/11/23

2023-07-11 11:18:16 ET Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were down more than 8% as of 10:45 a.m. ET on Tuesday after the biotech announced a public stock offering. The stock is up more than 26% so far this year. Iovance specializes in tumor infiltrating lympho...

2023-07-11 10:06:43 ET Gainers: CytoMed Therapeutics ( GDTC ) +128% . Eloxx Pharmaceuticals ( ELOX ) +29% . UpHealth ( UPH ) +13% . Virios Therapeutics ( VIRI ) +13% . Acumen Pharmaceuticals ( ABOS ) +9% . Losers: Jou...

2023-07-11 09:26:40 ET The Nasdaq Composite (NASDAQINDEX: ^IXIC) has performed extraordinarily well in 2023, getting off to its best first half of a year since the 1980s. Even though it has already recovered a lot of its lost ground from 2022's bear market, the Nasdaq has held up we...

2023-07-11 06:41:21 ET Summary Rite Aid's shares fell amid reports that the company is considering a Chapter 11 filing to address liabilities related to its opioid exposure; a bankruptcy filing is not confirmed or imminent. Berkshire Hathaway Energy is set to buy Dominion Energy's...

2023-07-11 05:44:50 ET The New Era For Commercial Banking Recession Risk - Expecting The Unexpected Jobs And Earning Data Support Continued Hot Economy For further details see: Biggest stock movers today: Iovance Biotherapeutics and Viridian Therapeutics

2023-07-11 01:30:52 ET Iovance Biotherapeutics ( NASDAQ: IOVA ) on Monday announced pricing of an underwritten public offering of 20 million shares of its common stock at a $7.50 per share. The stock is down about 10% to $7.92 after-hours on Monday...

2023-07-10 18:11:11 ET Summary Iovance Biotherapeutics, Inc. had a positive Type B Pre-Phase 3 meeting with the FDA, whereby IOV-LUN-202 trial will be allowed for Accelerated Approval of LN-145 for the treatment of NSCLC patients. Positive preliminary results achieved in registrat...

2023-07-10 17:03:22 ET Iovance Biotherapeutics ( NASDAQ: IOVA ) on Monday announced a proposed stock offering of up to $150M. Shares of IOVA fell 9% to $8 after hours. "All of the shares in the offering are to be sold by Iovance ( IOVA )," the company said in a s...

2023-07-10 07:25:23 ET Citing FDA feedback, Iovance Biotherapeutics ( NASDAQ: IOVA ) announced Monday that the design for the company’s ongoing IOV-LUN-202 trial for the lung cancer candidate LN-145 could be acceptable for a potential accelerated approval. The FDA indicat...

Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC) Preliminary Clinical Data in Post-Anti-PD-1 NSCLC Demonstrated a 26.1% Objective Response Rate (ORR) in Registrational IOV-LUN-...